Document is current

Article History

Received: 30 October 2018

Accepted: 1 April 2019

First Online: 7 May 2019

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests relevant to this work. DBJ is on advisory boards for Array, BMS, Genoptix, Incyte, Merck, and has received research funding from BMS and Incyte. JMB receives consulting fees from Novartis and grant funding from Incyte and Genentech. Luis A. Diaz (LAD) is a member of the board of directors of Personal Genome Diagnostics (PGDx) and Jounce Therapeutics. LAD holds equity in PapGene, PGDx and Neophore. He is a paid consultant for PGDx and Phoremost. He is an uncompensated consultant for Merck. LAD is an inventor of multiple patents related to technology for circulating tumor DNA analyses and mismatch repair deficiency for diagnosis and therapy (WO2016077553A1) from Johns Hopkins University. These licenses and relationships are associated with equity or royalty payments to LAD. The terms of all these arrangements are being managed by Johns Hopkins and Memorial Sloan Kettering in accordance with their conflict of interest policies. In addition, in the past 5 years, LAD has participated as a paid consultant for Merck and for one-time engagements with Caris, Lyndra, Genocea Biosciences, Illumina and Cell Design Labs.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.